Courtesy of Antisense Therapeutics Ltd. Antisense strategies use polymeric nucleic acids or nucleic acid analogs to bind to and silence specific messenger RNAs. The silencing can be caused either by ...
Gene silencing by RNA interference (RNAi) has become a powerful tool for functional genomics. In the January 25 Science, Tijsterman et al. report a gene-silencing method induced by short (25 ...
As people age, it becomes harder to know who is on track for healthy years ahead and who may be at higher risk for serious decline. A new study suggests that part of the answer may already be ...
HOUSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a ...
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/q3z4pf/pharmasphere) has announced the addition of the "PharmaSphere ...
These new preclinical platform data further highlight the potential of Axiomer EONs in preparation for clinical development and supporting discovery of potential new therapeutic applications. The ...
San Francisco, USA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The RNA-based Therapeutics and Vaccines Market was valued at USD 1,285.10 million in 2024 and is projected to reach approximately USD 2,320.54 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results